KEY POINTS
- This retrospective single-center study from Sichuan Cancer Hospital evaluated 30 patients with lung metastases treated using stereotactic body radiotherapy on a 1.5-T Elekta Unity MR-Linac between August 2021 and June 2025. All patients received 50 Gy in five fractions, with a median planning target volume of 30.6 cm³ (range 6.8–65.3 cm³). The objective was to determine whether contrast-enhanced CT could provide sufficiently reliable electron-density information for MR-based adaptive dose calculation without requiring an additional noncontrast planning CT.
- Patients underwent paired noncontrast planning CT (pCT) and contrast-enhanced CT (CHCT) acquisitions at the end-expiration respiratory phase. Investigators used structure-specific mean electron densities from each CT dataset to generate two synthetic CT configurations, psCT and csCT, within a common anatomical geometry. Treatment plans were recalculated in Monaco using Monte Carlo dose calculation, with identical target contours, beam arrangements, optimization parameters, and calculation settings. All patients were evaluated using a controlled adapt-to-shape simulation, irrespective of their actual clinical adaptive workflow.
- Contrast administration significantly altered electron-density estimates in several thoracic structures. Mean relative electron-density differences between noncontrast and enhanced CT were 12.03 ± 5.89% for the left lung, 13.36 ± 4.98% for the right lung, and 12.86 ± 5.03% for lung minus GTV (all p<0.001). Corresponding mean differences were 5.21% for the aorta, 3.45% for the heart, and 4.69% for the bronchial tree, whereas spinal cord and bone differences were only 0.33% and 0.30%, respectively.
- Despite these density differences, recalculated target doses remained relatively close to the original planning CT distribution. Mean target prescription-isodose coverage discrepancies were approximately 2.21% for csCT-based plans and 2.31% for psCT-based plans, each compared with the original pCT plan. The largest average deviation involved PTV D98, at 3.06% for csCT and 2.89% for psCT, while most other target metrics differed by approximately 1–3%. These differences primarily reflect comparisons between bulk-density synthetic CT and the original heterogeneous CT calculation; they should not be interpreted entirely as effects caused by contrast administration.
- Most OAR dose discrepancies were modest and remained below the applicable clinical constraints. Differences were generally less than 2% across evaluated structures, although several lung, heart, and spinal cord metrics showed statistically significant changes. Using the reported 3%/3 mm gamma criteria, mean passing rates exceeded 95% for PTV and evaluated OARs, with values above 99% for ribs and spinal cord. However, four original clinical plans already had reduced target prescription-dose coverage, approximately 84–90%, because lesions were adjacent to the ribs and OAR constraints were prioritized.
- Individual dosimetric deviations were not always negligible. The authors identified two patients with more pronounced target-dose differences, reaching 5.73% for Dmax and 6.61% for D2%, despite mean discrepancies generally remaining below 3%. The controlled simulation preserved the same anatomy and planning parameters across datasets, meaning it did not assess the full effects of daily organ deformation, registration uncertainty, different contrast phases, or clinical plan adaptation. The manuscript also reports 2%/2 mm gamma criteria in Methods but 3%/3 mm in the Results and figures, which requires clarification before using these results to define clinical acceptance standards.
CLINICAL TAKEAWAY
Contrast-enhanced CT-derived electron densities may be suitable for selected MR-Linac lung SBRT workflows using bulk-density assignment, potentially simplifying simulation and reducing redundant imaging. However, the demonstrated agreement comes from controlled recalculation rather than complete clinical adaptive treatment, and patient-specific dose verification remains important, particularly for lesions near tissue-density interfaces.